News & Updates

Treatment with liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) improved overall survival (OS) and progression-free survival (PFS) in patients aged ≥65 years with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP), according to a post hoc analysis of the phase III NAPOLI 3 trial presented at ESMO GI 2024.

The addition of a PARP inhibitor (PARPi), niraparib, to dostarlimab plus chemotherapy significantly improved progression-free survival (PFS) among patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, according to results from part 2 of the RUBY trial presented at ESMO Gyn 2024.

The addition of arsenic trioxide (ATO) to all-trans retinoic acid (ATRA) with idarubicin significantly improves event-free survival (EFS) compared with ATRA plus chemotherapy (CHT) in the first-line setting for patients with newly diagnosed, high-risk acute promyelocytic leukaemia (APL), according to the APOLLO trial presented at EHA 2024.

First-line immunotherapy results in improved median overall survival (OS) in patients with advanced Merkel cell carcinoma (MCC), reports a study, noting a better performance than chemotherapy in the real-world setting.

Rheumatoid arthritis (RA) appears to convey a 50-percent increase in the risk of lung cancer, with the risk increase even more pronounced for individuals with RA-interstitial lung disease (ILD), according to a study